ArticleOncogene2013

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.

S Postel-Vinay et al.PubMed ↗Publisher ↗

No numbers read from the abstract.